News Archive - Nicole Mlynaryk

Tissue-Specific Immunity May Be the Future, if We Can First Learn its Rules

UC San Diego study reveals critical insights into the complex biology of tissue-specific T cells, paving the way for a new branch of precision therapeutics in immunity, autoimmunity, and cancer.

New Look at an Ancient Disease: Study Finds Novel Treatment Targets for Gout

UC San Diego scientists identify a new molecular model and potential therapeutic target for gout, the most common form of inflammatory arthritis.

Enzyme Drives Cognitive Decline in Mice, Provides New Target for Alzheimer’s

UC San Diego researchers identify the PKCα enzyme as a promising therapeutic target in Alzheimer’s disease; a mutation that increases its activity led to biochemical, cellular and cognitive impairments in mice.

UC San Diego Sanford Stem Cell Institute Launches Stem Cells Into Space

The UC San Diego Sanford Stem Cell Institute leads its first space launch, sending stem cells into space aboard the International Space Station. The NASA-partnered study will take advantage of the microgravity environment of space to study accelerated aging in stem cells.

UC San Diego Awarded $8M to Expand Stem Cell Therapy Clinical Trials

UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to expedite clinical trials for patients with difficult-to-treat diseases.

Brain Organoids Reveal in Detail the Harms of Prenatal Alcohol Exposure

UC San Diego researchers used human brain organoids to study the effects of prenatal alcohol exposure on neural development, revealing significant harms in molecular detail.

Genetic Score Predicts Risk of Lethal Prostate Cancer

Researchers at UC San Diego report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer, which kills more than 34,000 men in the U.S. annually.

Treated or Not, COVID-19 Recurrence Seems Symptomatic for Some

UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.

UC San Diego Joins National Trial to Test Drug for Treating MPOX

UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.

‘Leaky’ Activity of Mutated Enzyme Underlies Neurodegenerative Disease

UC San Diego study finds enhanced PKCγ activity drives spinocerebellar ataxia type 14; suggests inhibiting the enzyme may have therapeutic potential